用镭-223治疗癌症骨转移患者尿中8-羟基-2′-脱氧鸟苷水平预测骨髓抑制。

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-03-30 Epub Date: 2025-03-18 DOI:10.21037/tcr-24-812
Satoru Monzen, Yoshihiko Kasai, Ryota Kinbara, Katsuhiko Suto, Yuki Morino, Kenji Terada, Andrzej Wojcik, Yasushi Mariya
{"title":"用镭-223治疗癌症骨转移患者尿中8-羟基-2′-脱氧鸟苷水平预测骨髓抑制。","authors":"Satoru Monzen, Yoshihiko Kasai, Ryota Kinbara, Katsuhiko Suto, Yuki Morino, Kenji Terada, Andrzej Wojcik, Yasushi Mariya","doi":"10.21037/tcr-24-812","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer bone metastasis (BM) from castration-resistant prostate cancer (CRPC) is the terminal stage of cancer, and it demonstrates a decreasing quality of life (QOL) due to skeletal-related events such as pain and bone fracture. Radium-223 dichloride administration is frequently selected as an internal radionuclide target therapy. This radioactive molecule has a potency of accumulation in bone minerals and emits alpha particles by decaying radium-223. These physical properties cause cellular damage to bone metastatic CRPC cells. However, some poor outcomes of patients are occasionally observed, such as bone marrow suppression. Therefore, in order to understand the status of deep BM, it is necessary to discover biomarkers that effectively reflect bone metabolism. In this study, we investigated whether urinal 8-hydroxy-2'-deoxyguanosine (8-OHdG), a one of oxidative stress marker, could be a predictive biomarker to identify whether radium-223 administration causes bone marrow suppression in patients.</p><p><strong>Methods: </strong>The urine and blood serum from four cancer patients with BM were collected and stored at -80 ℃ deep freezer until analysis. Following radiotherapeutic guidelines, three to six radium-223 internal radiotherapy doses were prescribed based on the patient, and it was terminated due to decreased therapeutic reserve.</p><p><strong>Results: </strong>The patients who were administered six radium-223 doses demonstrated upregulation of urinal 8-OHdG, serum C-terminal telopeptide of type I collagen (1CTP), and type I collagen cross-linked N-telopeptide (NTX) concentrations. Conversely, serum bone alkaline phosphatase (BAP) was downregulated. The patients who were administered less than five radium-223 doses exhibited urinal 8-OHdG downregulation and similar serum 1CTP, NTX, and BAP levels compared to before administration. In the patient who had bone marrow suppression, a negative correlation between time after first administration of radium-223 and urinal 8-OHdG was observed.</p><p><strong>Conclusions: </strong>These results suggest that a urinal 8-OHdG concentration has a potency of biomarker for bone marrow suppression under the administration of radium-223 in the patient with BM from CRPC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 3","pages":"1753-1763"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985201/pdf/","citationCount":"0","resultStr":"{\"title\":\"Predicting bone marrow suppression from urinal 8-hydroxy-2'-deoxyguanosine level during the treatment with radium-223 in patients with cancer bone metastasis.\",\"authors\":\"Satoru Monzen, Yoshihiko Kasai, Ryota Kinbara, Katsuhiko Suto, Yuki Morino, Kenji Terada, Andrzej Wojcik, Yasushi Mariya\",\"doi\":\"10.21037/tcr-24-812\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cancer bone metastasis (BM) from castration-resistant prostate cancer (CRPC) is the terminal stage of cancer, and it demonstrates a decreasing quality of life (QOL) due to skeletal-related events such as pain and bone fracture. Radium-223 dichloride administration is frequently selected as an internal radionuclide target therapy. This radioactive molecule has a potency of accumulation in bone minerals and emits alpha particles by decaying radium-223. These physical properties cause cellular damage to bone metastatic CRPC cells. However, some poor outcomes of patients are occasionally observed, such as bone marrow suppression. Therefore, in order to understand the status of deep BM, it is necessary to discover biomarkers that effectively reflect bone metabolism. In this study, we investigated whether urinal 8-hydroxy-2'-deoxyguanosine (8-OHdG), a one of oxidative stress marker, could be a predictive biomarker to identify whether radium-223 administration causes bone marrow suppression in patients.</p><p><strong>Methods: </strong>The urine and blood serum from four cancer patients with BM were collected and stored at -80 ℃ deep freezer until analysis. Following radiotherapeutic guidelines, three to six radium-223 internal radiotherapy doses were prescribed based on the patient, and it was terminated due to decreased therapeutic reserve.</p><p><strong>Results: </strong>The patients who were administered six radium-223 doses demonstrated upregulation of urinal 8-OHdG, serum C-terminal telopeptide of type I collagen (1CTP), and type I collagen cross-linked N-telopeptide (NTX) concentrations. Conversely, serum bone alkaline phosphatase (BAP) was downregulated. The patients who were administered less than five radium-223 doses exhibited urinal 8-OHdG downregulation and similar serum 1CTP, NTX, and BAP levels compared to before administration. In the patient who had bone marrow suppression, a negative correlation between time after first administration of radium-223 and urinal 8-OHdG was observed.</p><p><strong>Conclusions: </strong>These results suggest that a urinal 8-OHdG concentration has a potency of biomarker for bone marrow suppression under the administration of radium-223 in the patient with BM from CRPC.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 3\",\"pages\":\"1753-1763\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985201/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-24-812\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-812","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:去势抵抗性前列腺癌(CRPC)的癌症骨转移(BM)是癌症的终末期,由于骨骼相关事件如疼痛和骨折,其生活质量(QOL)下降。镭-223二氯化是经常选择作为内部放射性核素靶向治疗。这种放射性分子具有在骨矿物质中积累的潜力,并通过衰变镭-223释放α粒子。这些物理特性导致骨转移性CRPC细胞的细胞损伤。然而,偶尔也会观察到患者的一些不良结局,如骨髓抑制。因此,为了了解深部骨代谢的状况,有必要发现有效反映骨代谢的生物标志物。在这项研究中,我们研究了尿中8-羟基-2'-脱氧鸟苷(8-OHdG),一种氧化应激标志物,是否可以作为一种预测性生物标志物来识别镭223是否会导致患者骨髓抑制。方法:收集4例肿瘤BM患者的尿液和血清,-80℃冷冻保存待分析。根据放射治疗指南,根据患者规定了3至6次镭-223内部放射治疗剂量,由于治疗储备减少而终止。结果:接受6剂镭-223治疗的患者表现出尿8-OHdG、血清I型胶原c -末端末端肽(1CTP)和I型胶原交联n -末端肽(NTX)浓度的上调。相反,血清骨碱性磷酸酶(BAP)下调。与给药前相比,给予少于5次镭-223剂量的患者表现出尿8-OHdG下调,血清1CTP、NTX和BAP水平相似。在骨髓抑制患者中,首次给药后的时间与尿中8-OHdG呈负相关。结论:这些结果表明,尿中8-OHdG浓度可作为CRPC患者在镭-223治疗下骨髓抑制的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Predicting bone marrow suppression from urinal 8-hydroxy-2'-deoxyguanosine level during the treatment with radium-223 in patients with cancer bone metastasis.

Background: Cancer bone metastasis (BM) from castration-resistant prostate cancer (CRPC) is the terminal stage of cancer, and it demonstrates a decreasing quality of life (QOL) due to skeletal-related events such as pain and bone fracture. Radium-223 dichloride administration is frequently selected as an internal radionuclide target therapy. This radioactive molecule has a potency of accumulation in bone minerals and emits alpha particles by decaying radium-223. These physical properties cause cellular damage to bone metastatic CRPC cells. However, some poor outcomes of patients are occasionally observed, such as bone marrow suppression. Therefore, in order to understand the status of deep BM, it is necessary to discover biomarkers that effectively reflect bone metabolism. In this study, we investigated whether urinal 8-hydroxy-2'-deoxyguanosine (8-OHdG), a one of oxidative stress marker, could be a predictive biomarker to identify whether radium-223 administration causes bone marrow suppression in patients.

Methods: The urine and blood serum from four cancer patients with BM were collected and stored at -80 ℃ deep freezer until analysis. Following radiotherapeutic guidelines, three to six radium-223 internal radiotherapy doses were prescribed based on the patient, and it was terminated due to decreased therapeutic reserve.

Results: The patients who were administered six radium-223 doses demonstrated upregulation of urinal 8-OHdG, serum C-terminal telopeptide of type I collagen (1CTP), and type I collagen cross-linked N-telopeptide (NTX) concentrations. Conversely, serum bone alkaline phosphatase (BAP) was downregulated. The patients who were administered less than five radium-223 doses exhibited urinal 8-OHdG downregulation and similar serum 1CTP, NTX, and BAP levels compared to before administration. In the patient who had bone marrow suppression, a negative correlation between time after first administration of radium-223 and urinal 8-OHdG was observed.

Conclusions: These results suggest that a urinal 8-OHdG concentration has a potency of biomarker for bone marrow suppression under the administration of radium-223 in the patient with BM from CRPC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信